Mast cell mediator pathways

"Mast cell mediator pathways" describes the diverse and interlinked signaling and secretory mechanisms by which mast cells respond to various external stimuli (allergens, pathogens, injury) by releasing pro-inflammatory and immune-regulating compounds, including histamine, proteases, eicosanoids, cytokines, and chemokines[1][3][5]. Activation typically occurs through specific cell-surface receptors, most commonly FcεRI, in response to IgE and antigen, but also through other receptors including KIT (stem cell factor receptor), pattern recognition receptors, and G protein-coupled receptors like MRGPRX2[4][6]. These pathways are centrally involved in allergic disease, host defense, tissue homeostasis, and certain neoplastic conditions. Although drugs can target specific proteins within these pathways (such as KIT or FcεRI), "mast cell mediator pathways" as a whole is not a discrete, single therapeutic target. There is significant therapeutic interest in modulating mast cell mediator release to treat allergic and inflammatory conditions, but targeting the entire pathway rather than specific nodes risks broad immunological effects and potential adverse outcomes[6].

Other names

Mast cell activation pathwaysMast cell degranulation pathwaysMast cell signaling cascadesMast cell mediator release pathways

Inhibition of receptor tyrosine kinase (KIT/c-kit inhibition suppresses mast cell survival and mediator release[2][6]) Blockade of IgE binding/FcεRI signaling (e.g., omalizumab, antisense targeting FcεRIβ)[4] Inhibition of G protein-coupled receptor signaling (e.g., antagonists of MRGPRX2)[4] Inhibition of transcription factor expression (e.g., GATA3 DNAzymes[4]) General inhibitors of mast cell mediator synthesis (corticosteroids) or release (antihistamines, cromolyn sodium)